{"type":"trials","record":{"id":41364,"source_id":"clinicaltrials-gov","external_id":"NCT07798375","title":"A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration","brief_summary":"This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD)","overall_status":"Not Yet Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Everest Medicines (China) Co.,Ltd.","enrollment":244,"countries":[],"start_date":"2026-09-01","completion_date":"2028-10-01","last_update_date":"2026-09-10","source_url":"https://clinicaltrials.gov/study/NCT07798375","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"ASCEND","age_range":"50 Years","comparator":"Aflibercept","organization":"Everest Medicines (China) Co.,Ltd.","interventions":["VIS-101 6.0mg Low concentration","VIS-101 6.0mg High concentration","VIS-101 9.0mg High concentration","Aflibercept (Eylea)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in BCVA from baseline to average of Weeks 20, 24, and 28 — From Baseline through Week 28","Change in BCVA from baseline — Throughout week 48","Dosing interval — Throughout week 48","Number of injections — Throughout week 44","Change in CST from baseline — Throughout week 28 and week 48","Proportion of participants with no intraretinal fluid — Throughout week48","Proportion of participants with no subretinal fluid — Throughout week48","Proportion of participants with no intraretinal and subretinal fluid — Throughout week48","Proportion of participants with no intraretinal cysts — Throughout week48","Proportion of participants with no retinal pigment epithelial (RPE) detachment — Throughout week48","Change in total area of CNV lesion from baseline — Throughout week 28 and 48","Change in total leakage area from baseline — Throughout week 28 and 48","Incidence and severity of post-treatment adverse events, treatment-related adverse events and serious adverse events —…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Neovascular Age Related Macular Degeneration(nAMD)","VIS-101 6.0mg Low concentration","VIS-101 6.0mg High concentration","VIS-101 9.0mg High concentration","Aflibercept (Eylea)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07798375","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-09-01 to 2028-10-01","comparator":"Aflibercept","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.799Z","intervention":["VIS-101 6.0mg Low concentration","VIS-101 6.0mg High concentration","VIS-101 9.0mg High concentration","Aflibercept (Eylea)"],"participants":244,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in BCVA from baseline to average of Weeks 20, 24, and 28 — From Baseline through Week 28","Change in BCVA from baseline — Throughout week 48","Dosing interval — Throughout week 48","Number of injections — Throughout week 44","Change in CST from baseline — Throughout week 28 and week 48","Proportion of participants with no intraretinal fluid — Throughout week48","Proportion of participants with no subretinal fluid — Throughout week48","Proportion of participants with no intraretinal and subretinal fluid — Throughout week48","Proportion of participants with no intraretinal cysts — Throughout week48","Proportion of participants with no retinal pigment epithelial (RPE) detachment — Throughout week48","Change in total area of CNV lesion from baseline — Throughout week 28 and 48","Change in total leakage area from baseline — Throughout week 28 and 48","Incidence and severity of post-treatment adverse events, treatment-related adverse events and serious adverse events —…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41364","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}